Europe - Frankfurt Stock Exchange - FRA:BBZA - CH0038389992
The current stock price of BBZA.DE is 51.8 EUR. In the past month the price increased by 6.69%. In the past year, price increased by 27.74%.
ChartMill assigns a technical rating of 10 / 10 to BBZA.DE. When comparing the yearly performance of all stocks, BBZA.DE is one of the better performing stocks in the market, outperforming 87.58% of all stocks.
BB Biotech AG provides investment services for biotechnology sector. The company is headquartered in Schaffhausen, Schaffhausen and currently employs 86 full-time employees. The company went IPO on 2006-11-08. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
The current stock price of BBZA.DE is 51.8 EUR. The price decreased by -1.33% in the last trading session.
BBZA.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.